Evidence map›Paper›PMID 40024258›Full record

ReviewThe Lancet. Microbe2025

Role of non-human primate models in accelerating research and developing countermeasures against Zika virus infection.

Amanda Li, Lark L Coffey, Emma L Mohr, Jessica Raper, Ann Chahroudi, Karla K Ausderau, Matthew T Aliota, Thomas C Friedrich, Ann M Mitzey, Michelle R Koenig and 13 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Microbe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Amanda LiDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.
Lark L CoffeyDepartment of Pathology, Microbiology, and Immunology, University of California, Davis, Davis, CA, USA.
Emma L MohrDepartment of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA; Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, USA.
Jessica RaperDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA.
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA.
Karla K AusderauDepartment of Kinesiology, University of Wisconsin-Madison, Madison, WI, USA; Waisman Center, University of Wisconsin-Madison, Madison, WI, USA.
Matthew T AliotaDepartment of Veterinary and Biomedical Sciences, University of Minnesota Twin Cities, St Paul, MN, USA.
Thomas C FriedrichDepartment of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Ann M MitzeyDepartment of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Michelle R KoenigWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Thaddeus G GolosDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Hannah K JaegerVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA.
Victoria H J RobertsDivision of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Beaverton, OR, USA.
Jamie O LoDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA; Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Beaverton, OR, USA.
Jessica L SmithVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA.
Alec J HirschVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA.
Daniel N StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA.
Christina M NewmanDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
David H O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA; Wisconsin National Primate Research Center, Madison, WI, USA.
Eve M LackritzCenter for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, MN, USA.
Koen K A Van RompayDepartment of Pathology, Microbiology, and Immunology, University of California, Davis, Davis, CA, USA; California National Primate Research Center, Davis, CA, USA.
Kristina M Adams WaldorfDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Washington National Primate Research Center, Seattle, WA, USA. Electronic address: adamsk@uw.edu.
Zika Expert Workgroup

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
WaNPRC Macaca nemestrina SPF Breeding ColonyU42OD011123 · OD · UNIVERSITY OF WASHINGTON · PI Richard Grant · 2012 to 2026
$34.4M
Zika virus pathophysiology during pregnancyP01AI132132 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI O'CONNOR, DAVID H. · 2018 to 2022
$10.2M
Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease riskU01AI153416 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI HARRIS, EVA · 2021 to 2025
$4.9M
JAK-STAT Control of Zika Virus-Induced Fetal InjuryR01AI143265 · NIAID · UNIVERSITY OF WASHINGTON · PI ADAMS WALDORF, KRISTINA M., GALE, MICHAEL · 2019 to 2023
$4.6M
Medical Scientist Training Program of Oregon Health & Science UniversityT32GM141938 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI CHEN, YABING · 2021 to 2025
$4.6M
Innate Immune Regulation of Zika Virus InfectionR01AI145296 · NIAID · UNIVERSITY OF WASHINGTON · PI COYNE, CAROLYN B, DIAMOND, MICHAEL S · 2019 to 2023
$4.1M
Early neural predictors and neuropathogenesis of sensorimotor neurodevelopmental deficits in macaque infants exposed to Zika virus in uteroR01AI153130 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI AUSDERAU, KARLA KAYE, MOHR, EMMA L · 2020 to 2024
$3.8M
NIAID NIH HHS P01 AI132132NIAID NIH HHS R01 AI132519NIAID NIH HHS R01 AI132563NIAID NIH HHS R01 AI138647NIAID NIH HHS R01 AI143265NIAID NIH HHS R01 AI145296NIAID NIH HHS R01 AI153130NIAID NIH HHS R01 AI176777NIAID NIH HHS R21 AI129479NIAID NIH HHS R56 AI132563NIAID NIH HHS U01 AI153416NICHD NIH HHS R01 HD086331NICHD NIH HHS R01 HD096741NIDA NIH HHS DP1 DA056493NIGMS NIH HHS T32 GM141938NIH HHS P51 OD010425NIH HHS P51 OD011092NIH HHS P51 OD011106NIH HHS P51 OD011107NIH HHS P51 OD011132NIH HHS U42 OD011123NINDS NIH HHS R01 NS120182Wellcome TrustWellcome Trust 226438/Z/22/Z
6 · The paper itself

Abstract

Zika virus, a mosquito-transmitted orthoflavivirus, has become a pathogen of global health concern ever since the virus caused an epidemic in Brazil in 2015 associated with approximately 700 000 laboratory-confirmed cases of congenital microcephaly. The subsequent spread of the epidemic in 2016 resulted in a wide spectrum of congenital neurological, ophthalmological, and developmental abnormalities across the Americas, Africa, and Asia. In this context, non-human primate models have become essential tools for Zika virus research to understand the pathogenesis of congenital brain injury and perinatal complications and for developing and testing medical countermeasures such as vaccines, diagnostics, and therapeutics. Fetal brain injury has been observed across various non-human primate species and is influenced by factors such as the Zika virus strain, gestational age at inoculation, and inoculation dose and route. Miscarriages are also seen as common outcomes of first trimester Zika virus infections. This Series paper reviews the diverse non-human primate models currently used for Zika virus research to mitigate the public health effects of future Zika virus epidemics.

Indexed as

Disease Models, AnimalZika VirusZika Virus InfectionAnimalsFemaleHumansMicrocephalyPregnancyPrimates

Identifiers

PMID40024258
PMCPMC12145256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.